The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection
NCT03596827 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2019-03-20
Summary
The existing diarrhoeagenic Escherichia coli (E. coli) challenge model is already suitable for dietary interventions in its current form, targeted to impact on the immediate clinical symptoms upon E. coli infection. In order to make the model also suitable for dietary interventions that are aimed at support of the protective response against reinfection, the immune response triggered by the primary infection should be suboptimal. The MIRRE pilot study is set up to determine how much the primary inoculation dose of diarrheagenic E. coli should be lowered in order to result in a reduced protective response upon a secondary infection.
Conditions
Interventions
- BIOLOGICAL
-
E. coli strain E1392-75-2A dose 1E10 CFU
Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
- BIOLOGICAL
-
E. coli strain E1392-75-2A dose 1E9 CFU
Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
- BIOLOGICAL
-
E. coli strain E1392-75-2A dose 1E8 CFU
Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
- BIOLOGICAL
-
E. coli strain E1392-75-2A dose 1E7 CFU
Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
- BIOLOGICAL
-
E. coli strain E1392-75-2A dose 1E6 CFU
Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
Sponsors & Collaborators
-
FrieslandCampina
collaborator INDUSTRY -
NIZO Food Research
lead OTHER
Principal Investigators
-
Melle van Schaik · NIZO Food Research
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-09-26
- Primary Completion
- 2018-11-13
- Completion
- 2019-02-28
Countries
- Netherlands
Study Locations
More Related Trials
-
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
NCT00350298 ·Status: COMPLETED ·Phase: PHASE2
-
Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe
NCT01630096 ·Status: UNKNOWN ·Phase: PHASE4
-
Clostridioides Difficile Controlled Human Infection Model
NCT06702345 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Low-dose Challenge Model With Enterotoxigenic E Coli
NCT00844493 ·Status: COMPLETED ·Phase: PHASE1
-
Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection
NCT03353506 ·Status: COMPLETED ·Phase: PHASE2
-
Screening to Prophylax Against Clostridium Difficile Infection -
NCT02996487 ·Status: COMPLETED ·Phase: PHASE4
-
Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose
NCT06290089 ·Status: COMPLETED ·Phase: NA
-
Enteroaggregative E.Coli (EAEC)
NCT00362869 ·Status: TERMINATED ·Phase: PHASE1
-
Addition of Lactobacillus to Metronidazole in Treatment of CDAD
NCT00304863 ·Status: WITHDRAWN ·Phase: PHASE4
-
Identification of Correlates of Protection Against Shigella and Enterotoxigenic Escherichia Coli Infections
NCT01638039 ·Status: UNKNOWN ·Phase: NA
-
Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection
NCT03834038 ·Status: COMPLETED ·Phase: NA
-
The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation
NCT03621657 ·Status: COMPLETED ·Phase: PHASE2
-
Protective Immunity to Human Cholera in Bangladesh
NCT00349999 ·Status: COMPLETED
-
Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic Diarrhoea
NCT03045926 ·Status: COMPLETED ·Phase: PHASE1
-
AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment
NCT02896244 ·Status: COMPLETED
-
Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea
NCT00304876 ·Status: COMPLETED
-
Longitudinal Study of the Human Intestinal Microbiome
NCT00832286 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy
NCT00591357 ·Status: SUSPENDED ·Phase: PHASE4
-
Controlled Human Infection Model Challenge/Rechallenge
NCT04992520 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
NCT01232595 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia
NCT02127749 ·Status: COMPLETED ·Phase: NA
-
Probiotics Administration Via Colonoscopic Spray and Oral Administration in CDAD Patients
NCT05770726 ·Status: RECRUITING ·Phase: NA
-
Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile
NCT02857582 ·Status: COMPLETED ·Phase: PHASE2
-
Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli
NCT04574596 ·Status: COMPLETED
-
Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection
NCT05709184 ·Status: RECRUITING ·Phase: NA